Board of Directors

John M. Dineen
Chairman of the Board

John M. Dineen has served as the independent Chair of the Board of Syneos Health since December 2018. Mr. Dineen brings to the role more than 30 years of healthcare, technology and international management experience, most recently serving as Chief Executive Officer of GE’s Healthcare business from 2008 to 2014. Previously, Mr. Dineen spent more than two decades in a variety of other global leadership positions within GE, including President and Chief Executive Officer of GE Transportation, President of GE Plastics, General Manager of GE’s Power Equipment business, and General Manager of GE’s Appliances, Microwave and Air-Conditioning businesses.

Since 2015, Mr. Dineen has served as an operating advisor of the investment firm Clayton, Dubilier & Rice LLC. He also currently serves on the Board of Directors of Cognizant Technology Solutions Corporation (Nasdaq:CTSH), a leading provider of information technology, consulting, and business process services, where he serves on the Finance and Strategy Committee, and Governance and Sustainability Committee. He also currently serves as the chair of the boards of directors of Healogics and Carestream Dental. Mr. Dineen received Bachelor’s degrees in Biology and Computer Science from the University of Vermont where he now serves on the board of trustees.

Chairman of the Board
Todd M. Abbrecht
Director

Todd M. Abbrecht is an independent director who joined our Board in August 2017 and is a member of the Compensation and Management Development Committee. Since 1992, Mr. Abbrecht has served in various roles at THL, a private equity firm, where he is currently Co-Chief Executive Officer and a member of the firm’s management committee. Prior to joining THL, Mr. Abbrecht worked at Credit Suisse First Boston in its mergers and acquisitions department. Mr. Abbrecht currently serves on the board of directors of CSafe Global, PCI Pharma Services Inc. where he serves on the Compensation Committee, Professional Physical Therapy, Inc. where he also serves on the Compensation Committee, and is on the Board of Trustees of Joslin Diabetes Center. Mr. Abbrecht has previously served on the boards of directors of Party City Holdco (NYSE:PRTY), Aramark Holdings Corp (NYSE: ARMK), Fogo de Chao (formerly Nasdaq:FOGO), Curo Health Services, Inc., Juvare Holdings, Inc., Healthcare Staffing Services, Inc., and Intermedix Corporation. Mr. Abbrecht earned his BSE in finance from the Wharton School of the University of Pennsylvania and his MBA from Harvard Business School.

Thomas Allen
Director

Thomas Allen is an independent director who joined our Board in August 2017 and is a member of the Nominating and Corporate Governance Committee. Mr. Allen has served as Managing Director, Advent International Ltd, an affiliate of Advent focusing on investments in the healthcare sector, since January 2014. He has worked at Advent since 2004. Prior to joining Advent, he worked at Arthur Andersen and KPMG as part of the firms’ London private equity teams. Mr. Allen is currently a member of the board of Mediq, a provider of medical devices and care solutions, and a member of the board of Advent International Ltd. Mr. Allen is also on the Board of Directors of Zentiva Group, a leading European generics pharmaceutical company, where he serves on the Advisory Committee and Remuneration Committee, GLOBAL MENSA S.L., the holding company of Vitaldent, a Spanish network of dental care clinics, and Invest Europe, a private equity industry association. Mr. Allen previously served on the board of Priory Group. Mr. Allen received his Bachelor of Arts degree in economics from the University of Manchester and is a qualified accountant.

Bernadette Connaughton
Director

Bernadette Connaughton is an independent director who joined our board in November 2019 and is a member of the Audit Committee. She hasthree decades of experience in global strategic and leadership roles within large pharma. Ms. Connaughton spent her career at Bristol-Myers Squibb (NYSE: BMY), building a consistent track record of improving operational models, achieving sales growth and improving profitability. She most recently served as President Intercontinental, including China, Latin America, Central and Eastern Europe and the Middle East. In this role, she developed successful, multi-year commercialization strategies for a number of oncology, virology and immunology products. Ms. Connaughton currently serves on the Board of Directors of Zealand Pharma A/S (Nasdaq:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, where she serves on the Audit Committee and Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biotechnology company focused on novel biological and drug delivery approaches, where she serves on the Compensation Committee. She also serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Visterra, Inc. From 2014 to 2016, she served on the Patient Access and European Markets Committees of the European Federation of Pharmaceutical Industries and Associations. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.

Linda A. Harty
Director

Linda A. Harty is an independent director who joined our Board in March 2017, served as our Lead Independent Director from August 2017 to December 2018, and is a member of the Audit Committee and Compensation and Management Development Committee. From February 2010 to April 2017, Ms. Harty served as Vice President, Treasurer of Medtronic plc (NYSE:MDT), a global company specializing in medical technology, services and solutions. Ms. Harty also served as Executive Vice President, Treasurer at Cardinal Health (NYSE:CAH) and has held financial leadership positions at RTM Restaurant Group, BellSouth, ConAgra and Kimberly-Clark. Ms. Harty is on the board of directors at Parker Hannifin (NYSE:PH), a Fortune 250 global leader in motion and control technologies, where she serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Ms. Harty is also on the board of directors of Wabtec Corporation (NYSE: WAB), a Fortune 500 leading global provider of equipment, systems, digital solutions and value-added services for freight and transit rail, where she serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Ms. Harty is also on the board of directors of Chart Industries (NYSE: GTLS), a leading global manufacturer of highly engineered equipment servicing multiple market applications in the energy and industrial gas markets, where she serves as a member of the Audit Committee. Ms. Harty earned her undergraduate degrees in finance and economics from the University of Wisconsin – Oshkosh, and furthered her studies in accounting at Georgia State University, passing the CPA exam in 1991.

Financial Expert
William E. Klitgaard
Director

William E. Klitgaard is an independent director who joined our Board in March 2017, and is the Chair of the Audit Committee. Mr. Klitgaard provides consulting services to private equity firms as well as start-up and early-phase companies. From 2020 to 2021, Mr. Klitgaard served as an Operating Executive at Avista Capital Partners, a leading private equity firm focused on healthcare. From 2015 to 2016, Mr. Klitgaard served as President of Enlighten Health, a division of LabCorp (NYSE:LH) that focuses on innovation and creation of new information-based services utilizing core assets of LabCorp and Covance, Inc. Previously, he spent 19 years at Covance, one of the world’s largest contract research organizations, where he served for three years as Corporate Senior Vice President and Chief Information Officer, and nearly twelve years as Corporate Senior Vice President and Chief Financial Officer. Prior to his time at Covance, Mr. Klitgaard held finance leadership positions at Kenetech Corporation, a wind turbine manufacturer, and Consolidated Freightways, Inc., a freight service and logistics company.

Mr. Klitgaard currently serves on the board of directors of XIFIN, Inc., a health information technology company, and Inform Diagnostics, an anatomic pathology laboratory services company. Mr. Klitgaard previously served on the board of directors and Audit Committee of Certara, L.P., Bioclinica, Inc., and Liaison Technologies. Mr. Klitgaard completed his undergraduate studies in economics at the University of California at Berkeley, followed by his Master’s degree at the Sloan Management School, Massachusetts Institute of Technology.

Financial Expert
Alistair Macdonald
Chief Executive Officer and Director

He joined our Company in 2002 and has served in various senior leadership roles during that time. Prior to his current role, Mr. Macdonald most recently served as our President from January 2015 to October 2016 and as Chief Operating Officer from January 2013 to October 2016. He also served as President, Clinical Development Services from March 2012 to January 2013, Executive Vice President of our Global Oncology Unit from February 2011 to March 2012, Executive Vice President, Strategic Development from October 2009 to February 2011, and Senior Vice President, Biometrics from May 2002 to September 2009.

Mr. Macdonald currently serves on the Board of Directors of the Association of Clinical Research Organizations and Medicines Discovery Catapult, an independent, not-for-profit company, funded by an agency of the UK government. Mr. Macdonald received his Master of Science in Environmental Diagnostics from Cranfield University.

Kenneth F. Meyers
Director

Kenneth F. Meyers is an independent director who joined our Board in October 2016, and is the Chair of the Compensation and Management Development Committee and a member of the Nominating and Corporate Governance Committee. Mr. Meyers currently serves as Advisor to the Chief Executive Officer at Hillrom (NYSE:HRC), a global medical technology company, a position he has held since December 2020. He is also President at Ken Meyers Associates LLC, an executive coaching firm he founded in 2021. He previously served as Senior Vice President and Chief Human Resources Officer at Hillrom from 2015 to 2020, and prior to that held the same role at Hospira, Inc., a manufacturer and distributor of generic injectable pharmaceuticals, biosimilars and medical devices, from 2008 until its acquisition by Pfizer, Inc. in 2015. From 2004 to 2008, Mr. Meyers was a partner with Mercer/Oliver Wyman, a consulting firm specializing in leadership development. He also has served in senior human resources roles for Starbucks Coffee International, The Gymboree Corporation, Walt Disney Imagineering and United Technologies Corporation.

Mr. Meyers serves on the board of directors and the Nominating Committee for Elyssa’s Mission, a community-based non-profit organization dedicated to preventing teen suicide. He also is a member of the board of directors and Chair of the Compensation Committee for The Henry P. Kendall Foundation, an organization working to create healthy and sustainable food systems in New England, and a member of the board of directors of The Norfolk Charitable Foundation. Mr. Meyers holds a Bachelor’s degree with dual majors in International Business and Human Resource Management from the Wharton School of the University of Pennsylvania, and an MBA from the Harvard Business School.

Matthew E. Monaghan
Director

Matthew E. Monaghan is an independent director who joined our Board in October 2016, and serves as Chair of the Nominating and Corporate Governance Committee and is a member of the Audit Committee. Mr. Monaghan currently serves as President and Chief Executive Officer at Invacare Corporation (NYSE:IVC), a medical device manufacturer for the home and long-term healthcare markets, a position he has held since April 2015. Mr. Monaghan was named Chairman of the Invacare Board in May 2015. He previously served as Senior Vice President and General Manager, Global Hips and Reconstructive Research for Zimmer Biomet Holdings, Inc. (formerly known as Zimmer Holdings, Inc.) (NYSE:ZBH), a global company that designs, develops, manufactures and markets orthopedic reconstructive, spinal and trauma devices, dental implants, and related surgical products from 2014 to 2015. Mr. Monaghan also has served as Operating Executive for Texas Pacific Group from 2006 to 2009 and at Cerberus Capital Management from 2003 to 2005. He started his career with 13 years in the aerospace, medical and other industrial businesses of General Electric.

Mr. Monaghan is a trustee of Cleveland Clinic Avon Lake Hospital. Mr. Monaghan was a member of the board of directors of CD Diagnostics, Inc. from 2012 to 2016 and served as the chairman of the Audit Committee from 2012 to 2015 and as chairman of the board from 2015 to 2016. He holds a Bachelor’s degree in Mechanical Engineering from Cornell University, a Master’s degree in Mechanical Engineering from MIT and an MBA from INSEAD Business School in France.

David Wilkes, M.D.
Director

David S. Wilkes, M.D. is an independent director who joined our Board in June 2021. Dr. Wilkes currently serves as dean and as the James Carroll Flippin Professor of Medical Science at the University of Virginia School of Medicine, positions he has held since 2015. He previously served in positions of increasing responsibility at Indiana University School of Medicine, most recently as the Executive Associate Dean for Research Affairs and as the August M. Watanabe Professor of Medical Research between 2009 and 2015. Dr. Wilkes is the co-founder of ImmuneWorks Inc., a biotechnology start-up company, and has served as its chief scientific officer since 2006. Since 2013, he has served as the National Director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. This program seeks to increase underrepresented minority physician-scientists at leading medical schools in the United States. In 2020, he was elected to the National Academy of Medicine.

Dr. Wilkes currently serves on the board of directors of Baxter International Inc. (NYSE: BAX), a leading global medical products company, where he serves on the Quality, Compliance and Technology Committee. He also serves as a member of the board of trustees of Villanova University. He received his bachelor's degree in biology from Villanova University, his medical degree from Temple University School of Medicine, and conducted his residency at Temple University Hospital. Dr. Wilkes completed a post-doctoral fellowship in pulmonary and critical care at University of Texas Southwestern Medical Center. Dr. Wilkes is a military veteran, having served three years as a major in the U.S. Air Force Medical Corps.